Kumar Vivek, M.D.

1.) Single-Cell Mass Cytometry Analysis of the Human Endocrine Pancreas.
Wang YJ, Golson ML, Schug J, Traum D, Liu C, Vivek K, Dorrell C, Naji A, Powers AC, Chang KM, Grompe M, Kaestner KH.
Cell Metab. 2016 Oct 11;24(4):616-626. doi: 10.1016/j.cmet.2016.09.007.
PMID: 27732837

2.)Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets.
Kameswaran V, Bramswig NC, McKenna LB, Penn M, Schug J, Hand NJ, Chen Y, Choi I, Vourekas A, Won KJ, Liu C, Vivek K, Naji A, Friedman JR, Kaestner KH.
Cell Metab. 2014 Jan 7;19(1):135-45. doi: 10.1016/j.cmet.2013.11.016.
PMID: 24374217 

3.)Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol.
Rickels MR, Liu C, Shlansky-Goldberg RD, Soleimanpour SA, Vivek K, Kamoun M, Min Z, Markmann E, Palangian M, Dalton-Bakes C, Fuller C, Chiou AJ, Barker CF, Luning Prak ET, Naji A.
Diabetes. 2013 Aug;62(8):2890-7. doi: 10.2337/db12-1802.
PMID: 23630300 

4.)Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.
Parsons RF, Yu M, Vivek K, Zekavat G, Rostami SY, Ziaie AS, Luo Y, Koeberlein B, Redfield RR, Ward CD, Migone TS, Cancro MP, Naji A, Noorchashm H.
Transplantation. 2012 Apr 15;93(7):676-85. doi: 10.1097/TP.0b013e318246621d.
PMID: 22262127

5.)Underutilization of A2 ABO incompatible kidney transplantation.
Redfield RR, Parsons RF, Rodriguez E, Mustafa M, Cassuto J, Vivek K, Noorchashm H, Naji A, Levine MH, Abt PL.
Clin Transplant. 2012 May-Jun;26(3):489-94. doi: 10.1111/j.1399-0012.2011.01543.x.
PMID: 22032287

6.)Essential role for B cells in transplantation tolerance.
Redfield RR 3rd, Rodriguez E, Parsons R, Vivek K, Mustafa MM, Noorchashm H, Naji A.
Curr Opin Immunol. 2011 Oct;23(5):685-91. doi: 10.1016/j.coi.2011.07.011. Review.
PMID: 21982511

7.)Primary B cell repertoire remodeling to achieve humoral transplantation tolerance.
Parsons RF, Redfield RR 3rd, Rodriguez E, Mustafa MM, Vivek K, Murayama M, Naji A, Noorchashm H.
Semin Immunol. 2012 Apr;24(2):109-14. doi: 10.1016/j.smim.2011.08.016. Review.
PMID: 21978627

8.)Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance.
Vivek K, Mustafa MM, Rodriguez E, Redfield RR 3rd, Parsons RF, Rostami S, Migone TS, Cancro MP, Naji A, Noorchashm H.
Immunol Res. 2011 Oct;51(1):1-4. doi: 10.1007/s12026-011-8246-6. Review.
PMID: 21948256

9.)Auisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes.
Parsons RF, Vivek K, Rostami SY, Zekavat G, Ziaie SM, Luo Y, Koeberlein B, Redfield RR, Cancro MP, Naji A, Noorchashm H.
J Immunol. 2011 Jan 1;186(1):614-20. doi: 10.4049/jimmunol.1002873.
PMID: 21084661 

10.)B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.
Parsons RF, Vivek K, Redfield RR 3rd, Migone TS, Cancro MP, Naji A, Noorchashm H.
Transplant Rev (Orlando). 2010 Oct;24(4):207-21. doi: 10.1016/j.trre.2010.05.004. Review.
PMID: 20655723

11.)B-cell tolerance in transplantation: is repertoire remodeling the answer?
Parsons RF, Vivek K, Redfield RR, Migone TS, Cancro MP, Naji A, Noorchashm H.
Expert Rev Clin Immunol. 2009 Nov;5(6):703.
PMID: 20161663 

12.)Mechanism of action of lenalidomide in hematological malignancies.
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A.
J Hematol Oncol. 2009 Aug 12;2:36. doi: 10.1186/1756-8722-2-36. Review.
PMID: 19674465